Arun's mailing address filed with the SEC is #30, 1ST MAIN, J.P. NAGAR 3RD PHASE, BANGALORE, K7, 560078.
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv... és Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: